Singapore-based Dymon Asia Private Equity (DAPE) has teamed up with domestic engineering company Tee International to acquire a medical division of industrial services provider Sembcorp Environment for S$20 million ($15 million).
DCP Capital Partners, a private equity firm set up by the former heads of KKR’s China business, has agreed to invest an undisclosed sum in domestic heart valve developer Venus Medtech.
Brookfield Asset Management has submitted a A$4.35 billion ($3.3 billion) bid for Australian hospital operator Healthscope, trumping an offer made last month by a BGH Capital-led consortium.
Sequoia Capital China has led a $40 million Series B round of funding for MabSpace Bioscience, a Hong Kong-headquartered drug developer that specializes in cancer treatments.
Singapore’s GIC Private has led a $260 million Series B investment in China’s CStone Pharmaceuticals. The round, completed within two months, is said to be the largest biopharma Series B in the country to date.
WeDoctor, a Chinese online healthcare platform backed by Tencent Holdings, has received a $500 million round of funding – at a valuation of $5.5 billion – from Hong Kong-listed insurance company AIA Group and infrastructure and services conglomerate...
Ascletis, a Chinese drug developer that has received funding from C-Bridge Capital, has filed for an IPO in Hong Kong. It is set to be the first listing in the territory under new rules that allow companies with zero revenue or profit to go public.
Manipal Hospital Enterprises (MHEPL), an Indian hospital chain backed by TPG Capital, has submitted a revised buyout offer for Fortis Healthcare's (FHL) hospital operation that values the business at about INR83.5 billion ($1.2 billion).
Aslan Pharmaceutical, a Singapore-based drug developer that focuses on cancer treatments, has raised $42.2 million in its US IPO. The VC-backed company listed on the Taiwan Stock Exchange last June.
Qiming Venture Partners and Ruijan Capital have contributed RMB80 million ($12.6 million) to a Series B round for Wuxi Vision Pro, a Chinese ophthalmic medical device maker with operations in the US.
A healthcare fund managed by China Everbright has agreed to acquire the bulk of global medical equipment manufacturer Medtronic’s stake in Hong Kong-listed LifeTech Scientific Corporation.
Ping An Healthcare & Technology – operator of the Chinese healthcare-focused mobile app known as Ping An Good Doctor – closed flat on its Hong Kong trading debut following an HK$8.77 billion ($1.1 billion) IPO.
Chinese private equity firm CDH Investments has submitted a A$1.87 billion ($1.4 billion) bid for Australia-based Sirtex Medical. It comes days before Sirtex shareholders were due to vote on a lower offer from US-listed Varian Medical Systems.
Synyi, a Chinese artificial intelligence (AI) start-up that helps hospitals and medical research institutes process and manage data, has received RMB100 million ($15.7 million) in Series B funding led by GGV Capital.
Lilly Asia Ventures (LAV) has led a $25 million round for Avedro, a US-based ophthalmic pharmaceutical and medical devices company with a view to expanding in Asia.
Indian VC firm Unitus Ventures (formerly Unitus Seed Fund) has reached a first close of INR1 billion ($15 million) for its second early-stage impact investment fund.
Capital Group Private Markets (CGPM), a private equity affiliate of US-based Capital Group Companies, has led a $150 million Series E round for Chinese biopharmaceutical developer Innovent Biologics.
A group of PE investors led by BGH Capital and including AustralianSuper, GIC Private, Ontario Teachers’ Pension Plan (OTPP) and Canada Pension Plan Investment Board (CPPIB) has launched a buyout offer for Australian hospital operator Healthscope that...
Qiming has chosen to stick to its successful formula with its sixth US dollar-denominated vehicle, which recently closed at $935 million
Sequoia Capital China and Serica Partners have co-led an $11 million Series A round for US-based molecular diagnostics start-up NuProbe.
Ping An Healthcare & Technology - the PE-backed business that runs the healthcare-focused mobile app known as Ping An Good Doctor in China - is looking to raise up to HK$8.77 billion ($1.1 billion) in its Hong Kong IPO.
Indian healthcare service provider Fortis Healthcare (FHL) has formed a panel to evaluate several competing investment offers, including bids of INR61 billion ($933 million) from TPG Capital-backed Manipal Hospital Enterprises (MHEPL) and INR101 billion...
Qiming Venture Partners has closed two China-focused VC funds – including its sixth US dollar-denominated vehicle and fifth renminbi-denominated vehicle – and a newly-established US healthcare fund, with $1.39 billion in aggregate commitments.
Taimei Medical Technology, a Chinese cloud-based software provider that serves pharmaceutical companies and clinical research organizations (CROs), has raised RMB300 million ($48 million) in Series D funding.